IONS | tickerfilter.com

Fundamental analysis

38%

Profitability 16%

Dept financing 47%

Liquidity 75%

Performance 48%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.06%

1 Month

-4.83%

3 Months

-2.73%

6 Months

29.76%

1 Year

135.41%

2 Year

79.79%

Key data

Stock price

$75.16

P/E Ratio

0.00

DAY RANGE

$74.27 - $79.04

EPS

-$2.38

52 WEEK RANGE

$23.95 - $86.74

52 WEEK CHANGE

$131.03

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-31-2025

BETA

0.45

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,629,868

AVERAGE 30 VOLUME

$2,227,206

Company detail

CEO: Brett P. Monia
Region: US
Website: ionispharma.com
Employees: 800
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.

IONS - IONIS PHARMACEUTICALS INC